NCT05219578 - RTX-224 Monotherapy in Patients With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 12, 2022

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions

Non Small Cell Lung CancerCutaneous MelanomaHead and Neck Squamous Cell CarcinomaUrothelial CarcinomaTNBC - Triple-Negative Breast Cancer

Interventions

DRUG

RTX-224

RTX-224 monotherapy

Trial Locations (5)

Virginia Cancer Specialists, Fairfax

Sarah Cannon Research Institute, Nashville

HonorHealth, Scottsdale

USC Norris Comprehensive Cancer Center, Los Angeles

University of California San Francisco Health, San Francisco